M&A Deal Summary |
|
|---|---|
| Date | 2009-08-28 |
| Target | HySolv Technology |
| Sector | Life Science |
| Buyer(s) | Novartis |
| Sellers(s) | BTG |
| Deal Type | Divestiture |
| Deal Value | 10M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1996 |
| Sector | Life Science |
| Employees | 104,323 |
| Revenue | 51.8B USD (2022) |
Novartis is a global healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 31 |
| Sector (Life Science) | 4 of 26 |
| Type (Divestiture) | 1 of 3 |
| Country (United States) | 4 of 23 |
| Year (2009) | 1 of 2 |
| Size (of disclosed) | 16 of 16 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-06-04 |
Protez Pharmaceuticals
Malvem, Pennsylvania, United States Protez Pharmaceuticals, Inc. is a drug development company focused on novel antibiotics for the hospital market. Key program areas for Protez include a breakthrough broad spectrum carbapenem and two combination strategies for product line extensions of multiple established antibiotics. |
Buy | $400M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-09-01 |
Delenex Therapeutics AG
Schlieren, Switzerland Delenex Therapeutics AG is a clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. |
Sell | - |
| Category | Company |
|---|---|
| Founded | 1948 |
| Sector | Medical Products |
| Employees | 1,182 |
| Revenue | 823M USD (2018) |
BTG plc which develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as acute care pharmaceuticals. BTG has three key businesses, the largest of which is its Interventional Medicine portfolio which encompasses several peripheral interventional product lines. The interventional oncology franchise includes the TheraSphere® Y-90 radiotherapy microspheres and the GALIL™ cryoablation system, used to treat patients with liver, kidney, and other cancers. More than 840,000 people are expected to be diagnosed with liver cancer in 2018, and that number is expected to grow to 1.1 million by 2030. Kidney cancer is among the 10 most common cancers in both men and women.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2009) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-02-20 |
CLL Pharma - Opioid Agonist
France CLL Pharma - Opioid Agonist compound called BTG6001, is an orally active opioid agonist with a long duration of action, potentially reducing the amount of analgesic required for effective pain control. Owing to its unique receptor profile, BTG6001 is also expected to show a superior side effect profile compared with current opiate analgesics. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-07-15 |
Nordion - Targeted Therapies Division
Ottawa, Ontario, Canada Nordion, Inc. - Targeted Therapies Division manufactures and markets medical devices for treatment of inoperable primary liver cancer and metastatic liver cancer. The division is located in Ottawa, Canada. |
Buy | - |
